Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Transfer Hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN1566084A reveals novel water-soluble diamines enabling green asymmetric hydrogenation. Discover cost-effective API intermediate manufacturing solutions.
Patent CN116514707A discloses manganese-catalyzed asymmetric hydrogenation for high-purity pharmaceutical intermediates with significant cost and supply chain advantages.
Patent CN1694878A details advanced asymmetric transfer hydrogenation for high-purity pharmaceutical intermediates, offering scalable routes for cost-effective manufacturing.
Patent CN1328230C details asymmetric transfer hydrogenation of imines using Rh/Ru/Ir catalysts for high-purity pharmaceutical intermediates.
Advanced Ru-catalyzed synthesis of tetrahydrobenzylisoquinoline intermediates ensures superior optical purity and supply chain reliability for neuromuscular blocking agents.
Novel patent CN118724858B reveals high-yield synthesis. Offers supply chain reliability and cost reduction in pharmaceutical manufacturing for global buyers.
Novel asymmetric reduction route for Baloxavir Marboxil isomer. Eliminates chiral resolution, reduces cost, ensures supply chain stability for pharmaceutical manufacturing.
Patent CN103073492A details a green Ru-catalyzed transfer hydrogenation for Montelukast intermediates, offering significant cost reduction and supply chain reliability.
Novel biomimetic catalytic transfer hydrogenation for aprepitant intermediates. High yield, mild conditions, cost-effective manufacturing solution.
Patent CN104710359A details a chiral phosphoric acid catalyzed route for high-purity tetrahydroquinolines, offering significant cost and supply chain advantages for pharmaceutical manufacturing.
Novel transfer hydrogenation method for chiral hydroxycyclobutenone. Offers high selectivity, mild conditions, and cost-effective manufacturing for pharmaceutical intermediates.
Patent CN116514707B reveals manganese-catalyzed asymmetric hydrogenation for high-purity pharmaceutical intermediates. Achieve cost reduction and supply chain reliability.
Patent CN116514707B reveals manganese-catalyzed asymmetric hydrogenation for high-purity pharmaceutical intermediates, offering significant supply chain and cost advantages.
Patent CN109574797B reveals a green aqueous route for S-Int A. Achieve 99.9% ee and simplified purification for antifungal API manufacturing.
Novel Ru-catalyzed route for (S)-duloxetine intermediate offers high ee and yield without nitrogen protection, reducing manufacturing costs.
Patent CN106831549B details a novel asymmetric transfer hydrogenation route for Carbinoxamine. This method offers significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN114349687B reveals metal-free asymmetric hydrogenation. Enhances safety and reduces costs for pharmaceutical intermediates manufacturing supply chains.
Patent CN102264672A details a scalable route to chiral phenols using Ru-catalyzed transfer hydrogenation, offering cost reduction and high purity for pharmaceutical manufacturing.
Patent CN105001159A enables chiral phosphoric acid catalysis for quinoline-3-amine hydrogenation. Delivers high ee values and scalable pharmaceutical intermediate manufacturing solutions.
Patent CN114539328B reveals surfactant-promoted route enhancing yield and purity. Delivers supply chain stability and cost efficiency for global buyers.